COMMUNIQUÉS West-GlobeNewswire

Judo Bio Presents Data Demonstrating Sustained, Kidney-Selective Gene Silencing Across Species
20/10/2025
In vivo studies demonstrate robust and durable gene silencing across rodents and non-human primates Megalin-targeting ligand-siRNA conjugates (megalin-STRIKERs) deliver siRNAs to proximal tubular epithelial cells (PTECs [...]
Reverba Global Introduces ClinOps G.P.S.™ to Set a New Course for Clinical Trial Execution and Chart a Clearer Path from Protocol to Completion
20/10/2025
Comprehensive clinical operations navigation system aligns sponsors, CROs, investigators, sites and patients to improve trial planning, performance and outcomes Implementation with a top 15 global pharmaceutical company [...]
Synergy CHC Corp. (NASDAQ: SNYR) Expands FOCUSfactor® Functional Beverages Across New England Through Atlantic Importing Alliance
20/10/2025
WESTBROOK, Maine, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Synergy CHC Corp. (NASDAQ: SNYR), a leading consumer health and wellness company, today announced a strategic distribution partnership with Atlantic Importing Company [...]
MBX Biosciences to Participate in November Investor Conferences
20/10/2025
CARMEL, Ind., Oct. 20, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the [...]
BioAtla Presents Promising Interim Data from its Phase 1 Trial with BA3182 in Patients with Treatment Refractory Metastatic Adenocarcinoma at ESMO 2025
20/10/2025
Adverse events (AEs) generally transient and readily manageable; only 2 cases of cytokine release syndrome (CRS) Prolonged tumor control with increasing doses of BA3182; confirmed partial response (cPR) at 0.6 mg in a [...]
STRATA Skin Sciences Reinforces Market Leadership Following Key Litigation Milestones Against LaserOptek
20/10/2025
HORSHAM, Penn., Oct. 20, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative [...]
Vaxart to Present Research on Second-Generation Norovirus Oral Pill Vaccine Candidate at IDWeek 2025
20/10/2025
SOUTH SAN FRANCISCO, Calif., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT) (“Vaxart”), a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on its proprietary [...]
Oncotelic to Present at the LD Micro Main Event XIX
20/10/2025
AGOURA HILLS, Calif., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (OTCQB: OTLC), a biopharmaceutical company founded to discover, create, test, and deliver transformative medicines to treat cancer [...]
Galectin Therapeutics to Present at the H.C. Wainwright 9th Annual MASH Investor Conference
20/10/2025
NORCROSS, Ga., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced that the company management will [...]
Humber River Health Celebrates 10-Year Anniversary of Wilson Site
20/10/2025
Built on a vision of being lean, green and digital TORONTO, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Humber River Health proudly marks the 10 th anniversary of its Wilson Site, a decade since opening North America’s first [...]
New One-Year Data Reinforcing the Robust and Sustained Efficacy of EMPAVELI® (pegcetacoplan) in C3G and Primary IC-MPGN to be Presented at ASN Kidney Week
20/10/2025
Significant proteinuria reduction maintained at one year, regardless of immunosuppressant use or baseline proteinuria levels Complete proteinuria remission ( UPCR ≤0.5 g/g) achieved in one-third of patients and [...]
Replimune Announces FDA Acceptance of BLA Resubmission of RP1 for the Treatment of Advanced Melanoma
20/10/2025
Prescription Drug User Fee Act (PDUFA) target action date set for April 10, 2026 WOBURN, Mass., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering [...]
Medicenna Therapeutics Announces Participation in Upcoming Conferences
20/10/2025
TORONTO and HOUSTON, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company focused on the development of [...]
BPGbio and Icahn School of Medicine at Mount Sinai Publish Landmark Study on the Living Human Brain, Unlocking New Molecular Insights Into Neurodegenerative Disease
20/10/2025
New findings challenge the longstanding assumption that postmortem tissue accurately represents the living brain — and can reshape the future of research and drug development for Alzheimer’s, Parkinson’s, and other [...]
J-Star Applauds the Cooperation of Nasdaq and Ho Chi Minh City to Develop an International Financial Center in Vietnam
20/10/2025
TAICHUNG CITY, Taiwan, Oct. 20, 2025 (GLOBE NEWSWIRE) -- J-Star Holding Co., Ltd. (Nasdaq: YMAT) (“J-Star” or the “Company”), a leading provider of innovative carbon fiber and composite solutions across a wide range of [...]
Disc Medicine Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
20/10/2025
WATERTOWN, Mass., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ: IRON) (Disc), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments [...]
BioCryst to Report Third Quarter 2025 Financial Results on November 3
20/10/2025
RESEARCH TRIANGLE PARK, N.C., Oct. 20, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its third quarter 2025 financial results on Monday, November 3, [...]
WeightWatchers Collaborates With Amazon Pharmacy to Increase Medication Delivery Speed, Convenience and Savings For Members
20/10/2025
NEW YORK, Oct. 20, 2025 (GLOBE NEWSWIRE) -- WW International, Inc. (NASDAQ: WW) (“WeightWatchers” or the “Company”), the global leader in science-backed weight management, today announced a collaboration with Amazon [...]
Disc Medicine Provides Update on Hematology Portfolio and Outlines Near-Term Business Objectives and Anticipated Milestones
20/10/2025
Submitted a New Drug Application (NDA) for accelerated approval of bitopertin in erythropoietic protoporphyria (EPP) on September 29, 2025, and subsequently was awarded the FDA Commissioner’s National Priority Voucher ( [...]

Pages